hrp0089rfc7.5 | Fetal, Neonatal Endocrinology and Metabolism | ESPE2018

Alteration of Renal Corticosteroid Signaling Pathways in Preterm Infants: Neonatal Adaptation and Developmental Programming of Hypertension

Dumeige Laurence , Nehlich Melanie , Lhadj Christophe , Viengchareun Say , Xue Qiong-Yao , Pussard Eric , Lombes Marc , Martinerie Laetitia

Introduction: Prematurity, a worldwide health issue, is often associated with renal tubular immaturity leading to major salt loss, whose mechanisms remain poorly understood. Moreover, these premature infants are prone to develop hypertension early in adulthood.Objective: To study the ontogenesis of renal mineralocorticoid and glucocorticoid signaling pathways in preterm infants and to evaluate their respective role during neonatal adaptation and in the e...

hrp0094fc6.3 | Bone and Mineral Metabolism | ESPE2021

Off-label use of cinacalcet in pediatric primary hyperparathyroidism: a French multi-centre experience

Bernardor Julie , Flammier Sacha , Salles Jean-Pierre , Castanet Mireille , Martinerie Laetitia , Lienhardt-Roussie Anne , Amouroux Cyril , Linglart Agnes , Bacchetta Justine ,

Background: For adult patients who do not meet indications to surgery, the calcimimetic cinacalcet is approved for primary hyperparathyroidism (HPT), decreasing calcium and parathyroid hormone (PTH) levels. This drug is largely used in adults, but may be a challenge in daily practice in children, because of the risk of hypocalcemia, increased QT interval and drug interactions. A few pediatric cases have highlighted its potential interest in children with HPT; ...

hrp0097fc12.5 | Thyroid | ESPE2023

Teprotumumab in an adolescent with severe corticosteroid-resistant Graves ophthalmopathy: success but unexpected neurological manifestations

Atger-Lallier Laura , Elmaleh Monique , Pedron Beatrice , Storey Caroline , De Filippo Gianpaolo , Martinerie Laetitia , Leger Juliane , Carel Jean-Claude

Moderate to severe Graves ophthalmopathy (GO) is rare in children and most patients have mild GO. This complex inflammatory autoimmune disorder affecting the orbital fat and muscles is linked to circulating TSH receptor antibodies and involves the insulin-like growth factor-I receptor (IGF-IR) on orbital fibroblasts. Severe GO features include proptosis, diplopia and vision loss. Intravenous glucocorticoid pulse therapy is the first line medical treatment for moderate to sever...

hrp0095p2-153 | GH and IGFs | ESPE2022

Avascular necrosis of the hip as a rare complication of growth hormone therapy

van der Linde Annelieke , van Baelen Amber , van Bergen Christiaan

Background: Growth hormone therapy can be indicated for children who are born small for gestation age (SGA) (either birth weight or birth height < -2 SDS) without catch-up growth (height < -2.5 SDS) at age 4 years. Growth hormone therapy is considered a safe treatment.Case presentation: A 12-year-old girl was referred to the pediatric endocrinologist for short stature. She was born small for gestational age (birth ...

hrp0084p2-384 | Fat | ESPE2015

Obesity in ROHHADNET Syndrome: Does Cortisol Play a Role?

van Tellingen Vera , van Trotsenburg Paul

Background: ROHHADNET syndrome is characterised by rapid onset childhood obesity, hypoventilation, variable hypothalamic-pituitary and autonomic dysfunction, and neuroendocrine tumors in 30–40%. Autoimmunity and paraneoplastic syndrome have been proposed as possible pathophysiological mechanisms, but the exact aetiology remains unclear.Objective and hypotheses: We present the clinical course of ROHHADNET syndrome in a 17-year-old girl, with consecut...

hrp0084p3-697 | Diabetes | ESPE2015

Recurrent Ketosis after Prolonged Exercise in Type 1 Diabetes: The Need for Glycogen Replacement Strategies: Case Report

van Albada Mirjam , van Waarde Willie Bakker

Background: In diabetic athletes, glycogen depletion can contribute to the early development of starvation ketones as is demonstrated by our patient.Case presentation: Our patient, a 15-year-old male triathlete with type 1 diabetes for 5 years was referred to our tertiary center because of suboptimal regulation on continuous subcutaneous insulin infusion (CSII). He frequently awoke with nausea and ketosis, which was initially attributed to failure of ins...

hrp0095hdi1.2 | How Do I… Session 1 | ESPE2022

How do I manage severe obesity

van den Akker Erica

Pediatric severe obesity is a major threat to health and longevity. Around 7% of children worldwide have early onset severe obesity before the age of 7. Pediatric obesity is caused by an interplay of multiple factors: lifestyle, environmental, sociocultural, psychological, biological and genetic factors. Endocrine, monogenetic or syndromal causes are rare, but currently underdiagnosed and important to identify for the need of specific treatment. Cardiovascular risk factors and...

hrp0092s6.3 | Endocrinology Meets Diversity: Transgender Youth | ESPE2019

Gynecological Aspects and Fertility Issues in Transgender Adolescents

Trotsenburg Mick Van

This presentation briefly gives an overview of typical gynaecological issues and fertility options of transgender adolescents.Typical gynaecological complaints and treatment options will be addressed: e.g. amenorrhea induction prior to cross-sex hormones, irregular bleeding, dysmenorrhea, vaginal discharge but also the limitations of gynaecological examination in female asssigned adolescents.National and international organizations...

hrp0089s8.2 | Thyroid disorders | ESPE2018

Central Hypothyroidism – an Update

van Trotsenburg Paul

Central hypothyroidism can be best defined as lower than desirable thyroid hormone production and secretion because of insufficient stimulation of a normal thyroid gland by a defective pituitary or hypothalamus, resulting in a too low plasma or serum (free) thyroxine (FT4) concentration accompanied by a more or less normal thyrotropin (TSH) concentration. Central hypothyroidism can occur isolated or as part of multiple pituitary hormone deficiency and can be a congenital or ac...

hrp0082s4.1 | Recent Advances in Our Understanding of Hypothyroidism | ESPE2014

Management of Central Hypothyroidism

van Trotsenburg P

Central hypothyroidism (CeH) can be defined as a lower than desirable secretion of thyroid hormone by a normal thyroid gland resulting from (quantitative or qualitative) insufficient TSH secretion. Causes are congenital and acquired functional or anatomic defects of the hypothalamus, pituitary gland or both. CeH can be difficult to diagnose, especially in children without a history of brain defects or brain damaging treatment (e.g. irradiation), and when plasma FT4 concentrati...